You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023324022
Dec 2023100014
Jan 20246706
Feb 202456017
Mar 202484016
Apr 20249607
May 20243907
Jun 20244703
Jul 20249107
Aug 20244404
Sep 202462010
Oct 20243404
Nov 202450013
Dec 202460011
Jan 20256206
Feb 20251603
Mar 2025003
Apr 2025001
May 2025005
Jun 2025003
Total12320162